Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation.

CP: Cancer ChiP-seq EWSR1-ERG EWSR1-ETS EWSR1-FLI1 Ewing sarcoma enhancer microsatellites multi-omics pediatric sarcoma tumor heterogeneity

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
06 12 2022
Historique:
received: 02 12 2021
revised: 25 08 2022
accepted: 08 11 2022
entrez: 8 12 2022
pubmed: 9 12 2022
medline: 15 12 2022
Statut: ppublish

Résumé

Ewing sarcoma (EwS) is characterized by EWSR1-ETS fusion transcription factors converting polymorphic GGAA microsatellites (mSats) into potent neo-enhancers. Although the paucity of additional mutations makes EwS a genuine model to study principles of cooperation between dominant fusion oncogenes and neo-enhancers, this is impeded by the limited number of well-characterized models. Here we present the Ewing Sarcoma Cell Line Atlas (ESCLA), comprising whole-genome, DNA methylation, transcriptome, proteome, and chromatin immunoprecipitation sequencing (ChIP-seq) data of 18 cell lines with inducible EWSR1-ETS knockdown. The ESCLA shows hundreds of EWSR1-ETS-targets, the nature of EWSR1-ETS-preferred GGAA mSats, and putative indirect modes of EWSR1-ETS-mediated gene regulation, converging in the duality of a specific but plastic EwS signature. We identify heterogeneously regulated EWSR1-ETS-targets as potential prognostic EwS biomarkers. Our freely available ESCLA (http://r2platform.com/escla/) is a rich resource for EwS research and highlights the power of comprehensive datasets to unravel principles of heterogeneous gene regulation by chimeric transcription factors.

Identifiants

pubmed: 36476851
pii: S2211-1247(22)01644-8
doi: 10.1016/j.celrep.2022.111761
pmc: PMC10333306
mid: NIHMS1909974
pii:
doi:

Substances chimiques

Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111761

Subventions

Organisme : NHGRI NIH HHS
ID : R01 HG010885
Pays : United States

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nat Methods. 2009 Sep;6(9):677-81
pubmed: 19668202
Clin Cancer Res. 2007 Apr 15;13(8):2429-40
pubmed: 17438102
Mol Cancer Res. 2012 Jan;10(1):52-65
pubmed: 22080479
Cell Rep. 2022 Jun 14;39(11):110971
pubmed: 35705030
Cancer Cell. 2021 Jun 14;39(6):810-826.e9
pubmed: 33930311
Nucleic Acids Res. 2019 Oct 10;47(18):9619-9636
pubmed: 31392992
Epigenetics. 2014 Dec;9(12):1613-25
pubmed: 25625846
Cancer Discov. 2021 Nov;11(11):2884-2903
pubmed: 34021002
Oncogene. 2012 Mar 8;31(10):1287-98
pubmed: 21822310
BMC Bioinformatics. 2021 Aug 17;22(1):407
pubmed: 34404353
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
NAR Cancer. 2022 Jan 14;4(1):zcab052
pubmed: 35047826
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Surg Oncol. 2018 Dec;27(4):603-610
pubmed: 30449479
Nat Genet. 1994 Feb;6(2):146-51
pubmed: 8162068
Genes Cancer. 2015 Nov;6(11-12):452-61
pubmed: 26807198
PLoS One. 2009;4(3):e4932
pubmed: 19305498
Nat Commun. 2019 Sep 11;10(1):4128
pubmed: 31511524
PLoS One. 2017 Nov 1;12(11):e0186275
pubmed: 29091716
Oncotarget. 2016 Jul 5;7(27):41767-41780
pubmed: 27363011
Genome Res. 2012 Feb;22(2):259-70
pubmed: 22086061
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54
pubmed: 18626011
Genes Cancer. 2015 Mar;6(3-4):129-43
pubmed: 26000096
Cancer Cell. 2021 Jun 14;39(6):827-844.e10
pubmed: 34129824
Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37
pubmed: 11715049
Nature. 2020 Apr;580(7803):396-401
pubmed: 32296180
PLoS One. 2010 May 25;5(5):e10820
pubmed: 20520839
Cancer Cell. 2014 Nov 10;26(5):668-681
pubmed: 25453903
Nucleic Acids Res. 2015 Mar 11;43(5):2780-9
pubmed: 25712098
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Cancers (Basel). 2019 Mar 06;11(3):
pubmed: 30845695
Nucleic Acids Res. 2005 Nov 10;33(20):e175
pubmed: 16284200
Oncogene. 2017 Jun 22;36(25):3505-3514
pubmed: 28135250
Nat Genet. 2015 Sep;47(9):1073-8
pubmed: 26214589
Nat Med. 2017 Mar;23(3):386-395
pubmed: 28134926
Cell. 2017 Sep 21;171(1):163-178.e19
pubmed: 28844694
Bioinformatics. 2017 Aug 15;33(16):2575-2576
pubmed: 28383704
Front Oncol. 2021 May 25;11:684021
pubmed: 34113572
Oncogene. 2017 Feb 9;36(6):766-776
pubmed: 27375017
Methods Mol Biol. 2021;2226:265-284
pubmed: 33326109
Cancers (Basel). 2019 Aug 01;11(8):
pubmed: 31374935
Nature. 1992 Sep 10;359(6391):162-5
pubmed: 1522903
Science. 2018 Aug 31;361(6405):
pubmed: 30166462
Nucleic Acids Res. 1999 Jan 15;27(2):573-80
pubmed: 9862982
Rev Recent Clin Trials. 2017;12(1):19-23
pubmed: 28117008
PLoS One. 2013 Dec 02;8(12):e80060
pubmed: 24312454
Genome Biol. 2014 Jun 26;15(6):R84
pubmed: 24970577
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
J Proteome Res. 2018 Jan 5;17(1):618-634
pubmed: 29182335
Cancer Res. 2008 Apr 1;68(7):2176-85
pubmed: 18381423
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Oncotarget. 2017 Jan 3;8(1):458-471
pubmed: 27888797
PLoS One. 2008 Apr 16;3(4):e1965
pubmed: 18414662
Genome Biol. 2021 Jul 12;22(1):202
pubmed: 34253237
PLoS One. 2014 Aug 05;9(8):e104378
pubmed: 25093581
Front Genet. 2012 Mar 15;3:35
pubmed: 22435069
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Sci Signal. 2017 Oct 03;10(499):
pubmed: 28974650
J Clin Invest. 1994 Aug;94(2):489-96
pubmed: 8040301
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
Bioinformatics. 2011 Nov 1;27(21):2987-93
pubmed: 21903627
Genome Res. 2017 Dec;27(12):2050-2060
pubmed: 29097403
Cancer Genet Cytogenet. 1986 Apr 1;21(3):185-208
pubmed: 3004699
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Clin Orthop Relat Res. 2006 Sep;450:25-7
pubmed: 16951641
Acta Oncol. 2016 Sep - Oct;55(9-10):1145-1151
pubmed: 27549334
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Mol Cancer Res. 2017 Nov;15(11):1517-1530
pubmed: 28720588
Cancer Res. 2012 Sep 1;72(17):4494-503
pubmed: 22930730
Cancer Res. 2021 Oct 1;81(19):4994-5006
pubmed: 34341072
Mol Cell. 2022 Jul 7;82(13):2458-2471.e9
pubmed: 35550257
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
Oncogene. 2008 Oct 9;27(46):6034-43
pubmed: 18591936
Cell Cycle. 2008 Jan 15;7(2):250-6
pubmed: 18256529
J Cancer Res Clin Oncol. 2019 May;145(5):1273-1281
pubmed: 30895378
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
PLoS Genet. 2014 Jul 10;10(7):e1004475
pubmed: 25010205
Cancer Genet. 2012 Jun;205(6):304-12
pubmed: 22749036
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1307-16
pubmed: 25737553
Biochem Biophys Res Commun. 2010 Nov 5;402(1):129-34
pubmed: 20933505
Cell Cycle. 2009 Feb 1;8(3):498-504
pubmed: 19177017
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Front Oncol. 2015 Jul 20;5:162
pubmed: 26258070
Mod Pathol. 2017 Sep;30(9):1312-1320
pubmed: 28643791
Br J Cancer. 2002 Jun 5;86(11):1763-9
pubmed: 12087464
Acta Histochem. 2015 May-Jun;117(4-5):460-7
pubmed: 25765111
Genome Res. 2011 Jun;21(6):974-84
pubmed: 21324876
J Clin Oncol. 2015 Sep 20;33(27):3036-46
pubmed: 26304893
Genes Dev. 2018 Aug 1;32(15-16):1008-1019
pubmed: 30042132
Nat Methods. 2017 Jun;14(6):590-592
pubmed: 28436466
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
EBioMedicine. 2019 Sep;47:156-162
pubmed: 31427232
Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):449-53
pubmed: 21212061
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
Oncogene. 2018 Feb 8;37(6):798-809
pubmed: 29059150
Oncotarget. 2017 May 23;8(21):34141-34163
pubmed: 27191748
Nat Commun. 2020 May 15;11(1):2423
pubmed: 32415069
Methods Mol Biol. 2021;2226:15-25
pubmed: 33326090
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Methods Mol Biol. 2021;2226:49-64
pubmed: 33326093
Nat Commun. 2013;4:2612
pubmed: 24113773
Oncogene. 2001 May 31;20(25):3258-65
pubmed: 11423975
J Natl Cancer Inst. 2013 Apr 3;105(7):452-8
pubmed: 23434901
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Methods Mol Biol. 2021;2226:191-199
pubmed: 33326103
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
EMBO J. 1993 Dec;12(12):4481-7
pubmed: 8223458
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Cell Rep. 2015 Feb 24;10(7):1082-95
pubmed: 25704812
PLoS One. 2013 Jun 04;8(6):e66281
pubmed: 23750284
Oncotarget. 2017 Aug 4;9(2):1587-1601
pubmed: 29416716
Genome Res. 2013 Nov;23(11):1797-809
pubmed: 23940108

Auteurs

Martin F Orth (MF)

Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, 80337 Munich, Germany.

Didier Surdez (D)

INSERM Unit 830 "Genetics and Biology of Cancers," Institut Curie Research Center, 75005 Paris, France; Balgrist University Hospital, Faculty of Medicine, University of Zürich, 8008 Zürich, Switzerland.

Tobias Faehling (T)

Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.

Anna C Ehlers (AC)

Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.

Aruna Marchetto (A)

Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, 80337 Munich, Germany.

Sandrine Grossetête (S)

INSERM Unit 830 "Genetics and Biology of Cancers," Institut Curie Research Center, 75005 Paris, France.

Richard Volckmann (R)

Department of Oncogenomics, Amsterdam University Medical Centers (AUMC), 1105 Amsterdam, the Netherlands.

Danny A Zwijnenburg (DA)

Department of Oncogenomics, Amsterdam University Medical Centers (AUMC), 1105 Amsterdam, the Netherlands.

Julia S Gerke (JS)

Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, 80337 Munich, Germany.

Sakina Zaidi (S)

INSERM Unit 830 "Genetics and Biology of Cancers," Institut Curie Research Center, 75005 Paris, France.

Javier Alonso (J)

Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III, 28029 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CB06/07/1009, CIBERER-ISCIII), 28029 Madrid, Spain.

Ana Sastre (A)

Unidad Hemato-oncología Pediátrica, Hospital Infantil Universitario La Paz, 28029 Madrid, Spain.

Sylvain Baulande (S)

Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, 75005 Paris, France.

Martin Sill (M)

Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany; Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.

Florencia Cidre-Aranaz (F)

Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.

Shunya Ohmura (S)

Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.

Thomas Kirchner (T)

Institute of Pathology, Faculty of Medicine, LMU Munich, 80337 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, 80337 Munich, Germany; German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Stefanie M Hauck (SM)

Research Unit Protein Science and Metabolomics and Proteomics Core, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany.

Eva Reischl (E)

Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany.

Melissa Gymrek (M)

Division of Genetics, Department of Medicine, University of California, San Diego, San Diego, CA 92093, USA; Department of Computer Science and Engineering, University of California, San Diego, San Diego, CA 92093, USA.

Stefan M Pfister (SM)

Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany; Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; Department of Pediatric Hematology & Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Konstantin Strauch (K)

Institute of Medical Biometry, Epidemiology, and Informatics (IMBEI), University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany; Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany; Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, 81377 Munich, Germany.

Jan Koster (J)

Department of Oncogenomics, Amsterdam University Medical Centers (AUMC), 1105 Amsterdam, the Netherlands.

Olivier Delattre (O)

INSERM Unit 830 "Genetics and Biology of Cancers," Institut Curie Research Center, 75005 Paris, France.

Thomas G P Grünewald (TGP)

Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, 80337 Munich, Germany; Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany. Electronic address: t.gruenewald@dkfz-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH